Generation of iPSC-lines from two independent Takotsubo syndrome patients with recurrent Takotsubo events by Hübscher, Daniela et al.








Generation of iPSC-lines from two independent Takotsubo syndrome
patients with recurrent Takotsubo events
Hübscher, Daniela ; Rebs, Sabine ; Maurer, Wiebke ; Ghadri, Jelena R ; Dressel, Ralf ; Templin,
Christian ; Streckfuss-Bömeke, Katrin
Abstract: The Takotsubo syndrome (TTS) is characterized by acute transient left ventricular dysfunction
in the absence of obstructive coronary lesions. An enhanced ฀-adrenergic signaling and higher sensitivity
to catecholamine-induced-toxicity were identified as mechanisms associated with TTS. It is still elusive,
whether TTS patients with recurrent events show similar underlying signaling pathomechanism. Induced
pluripotent stem cell (iPSC)-lines were generated from skin fibroblasts of two independent female Takot-
subo syndrome patients with a severe phenotype characterized by recurrent TTS events. For reprogram-
ming, a non-integrative plasmid technique was used. All generated iPSCs maintained full pluripotency,
genomic integrity, and spontaneous in vitro and in vivo differentiation capacity.
DOI: https://doi.org/10.1016/j.scr.2020.101746






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Hübscher, Daniela; Rebs, Sabine; Maurer, Wiebke; Ghadri, Jelena R; Dressel, Ralf; Templin, Christian;
Streckfuss-Bömeke, Katrin (2020). Generation of iPSC-lines from two independent Takotsubo syndrome
patients with recurrent Takotsubo events. Stem Cell Research, 44:101746.
DOI: https://doi.org/10.1016/j.scr.2020.101746
Contents lists available at ScienceDirect
Stem Cell Research
journal homepage: www.elsevier.com/locate/scr
Lab Resource: Multiple Stem Cell Lines
Generation of iPSC-lines from two independent Takotsubo syndrome
patients with recurrent Takotsubo events
Daniela Hübscher (PhD)a,b, Sabine Rebs (MSc)a,b, Wiebke Maurer (MSc)a,b,
Jelena R. Ghadri (MD)c, Ralf Dressel (MD)b,d, Christian Templin (MD, PhD)c,
Katrin Streckfuss-Bömeke (PhD)a,b,⁎
a Clinic for Cardiology and Pneumonology, University Medical Center Goettingen, Goettingen, Germany
bDZHK (German Center for Cardiovascular Research), Goettingen, Germany
cUniversity Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
d Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
A B S T R A C T
The Takotsubo syndrome (TTS) is characterized by acute transient left ventricular dysfunction in the absence of obstructive coronary lesions. An enhanced β-
adrenergic signaling and higher sensitivity to catecholamine-induced-toxicity were identified as mechanisms associated with TTS. It is still elusive, whether TTS
patients with recurrent events show similar underlying signaling pathomechanism. Induced pluripotent stem cell (iPSC)-lines were generated from skin fibroblasts of
two independent female Takotsubo syndrome patients with a severe phenotype characterized by recurrent TTS events. For reprogramming, a non-integrative plasmid
technique was used. All generated iPSCs maintained full pluripotency, genomic integrity, and spontaneous in vitro and in vivo differentiation capacity.
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plasmids: pCXLE-hOct3/4-shp53-F (Addgene 27077),
pCXLE-hSK (Addgene 27078), pCXLE-hUL (Addgene
27080)
Multiline rationale Same disease, non-isogenic cell lines
Gene modification No
Type of modification N/A
Associated disease Takotsubo syndrome (TTS)
Gene/locus N/A
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1. Resource utility
The Takotsubo syndrome (TTS) is a transient cardiac disease, which
involves left ventricular apical akinesia. The pathomechanism of TTS is
still not fully understood. However, a genetic predisposition is de-
scribed. Therefore, we generated patient-specific induced pluripotent
stem cell (ps-iPSC)-lines from two non-related TTS-patients with a se-
vere phenotype, characterized as more than one TTS event.
2. Resource details
TTS is characterized by acute transient left ventricular dysfunction
in the absence of obstructive coronary lesions. TTS patients show
symptoms similar to the acute myocardial infarction. TTS is mostly
triggered by high emotional or physical stress resulting in a high ca-
techolamine level (Templin et al., 2015). The pathogenic mechanism
leading to TTS is still not completely clarified. However, a β-adrenergic
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overstimulation and a genetic predisposition were shown to play an
important role in TTS (Borchert et al., 2017). We isolated somatic cells
from TTS-patients, reprogrammed them into ps-iPSCs and differentiated
them into pure beating cardiomyocytes (iPSC-CMs). Using this
established in vitro ps-iPSC-TTS model, we were able to identify an
enhanced β-adrenergic signaling and higher sensitivity to catechola-
mine-induced toxicity as mechanisms associated with the TTS pheno-
type (Borchert et al., 2017). Until now it was not analyzed, whether TTS
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patients with recurrent TTS events show similar underlying signaling
pathomechanism. To analyze this circumstance, we established ps-iPSC-
TTS-lines from two non-related TTS patients with recurrent TTS events.
Therefore, skin fibroblasts of two independent female TTS patients
(patient 10 and 11) were reprogrammed into ps-iPSC-line by using a
non-integrating plasmid-system (Okita et al., 2011). All generated cell
lines show pluripotency characteristics as shown in Fig. 1. They showed
typical pluripotency morphology, were positive for alkaline phospha-
tase (ALP) staining and expressed typical pluripotency markers such as
OCT4, SOX2, LIN28 and TRA1-60 on protein level (Fig 1A). Expression
of pluripotency genes on mRNA level has been demonstrated by qPCR
in comparison to fibroblasts as a negative control and an already pub-
lished iPSC-line as positive control (Borchert et al., 2017) (Fig 1B). The
generated iPSC lines were authenticated by STR analysis compared to
their parental fibroblasts (archive of journal) and tested negative for
mycoplasma contamination (Supplementary Fig 1A) as well as for
episomal vectors by semiquantitative PCR (Supplementary Fig 1B). We
used a primer pair for EBNA-1 sequence derived from Epstein-Barr
virus, since EBNA-1 is part of the episomal vectors used for repro-
gramming (Okita et al., 2011). EBNA was expressed in the plasmids
used for reprogramming, but not in the generated 10-TTS or 11-TTS
lines (passage 25-82). To confirm the clearance of episomal plasmids in
the generated iPSC lines, we used a primer pair against the vector-de-
rived expression of OCT4 (pla) demonstrating expression of exogenous
OCT4 only in the plasmid pCXLE-hOCT3/4-shp53, but not in the gen-
erated cell lines. The sendai virus-generated iPSC-Line SV-iPSC NC
served as negative control for plasmid-generated iPSCs (Supplementary
Fig 1B).
Standard G-banding karyotype analysis was performed to test
genomic integrity and resulted in a normal karyotype of 10-TTS (pas-
sage 40) and 11-TTS (passage 26) (Fig 1C). The spontaneous differ-
entiation capacity of all generated iPSC lines was analyzed by embryoid
body formation in vitro and teratoma formation in immunodeficient
mice in vivo. The expression of proteins of all three germ layers as α-
smooth muscle actin (α-SMA) (Mesoderm), α-fetoprotein (AFP) (En-
doderm), and β-III-Tubulin (Ectoderm) were demonstrated in vitro (Fig
1D) and teratoma formation with tissue from all three germ layers was
shown in vivo (Fig 1E).
3. Materials and methods
All cells were cultured under humidified conditions at 37°C and 5%
CO2 saturation.
3.1. Somatic cell isolation
3.5-4 mm skin biopsies of the donors were taken aseptically and
placed in DMEM containing penicillin (100 U/mL)/streptomycin (100
µg/mL). The biopsy was cut into pieces and transferred in dishes con-
taining fibroblast growth medium (DMEM supplemented with 10 %
FCS, 1x NEAA, Glutamine (2 mmol/L), β-mercaptoethanol (50 µmol/L),
penicillin (50 U/mL)/streptomycin (50 µg/mL), bFGF (10 ng/mL)).
Transduction experiments were performed before passage 3.
3.2. Generation and culture of ps-iPSCs
For plasmid-based integration-free reprogramming, 4× 105 cells
were used for electroporation with the NHDF Nucleofector Kit (Lonza).
Suspended cells and 1-2 µg of the plasmids pCXLE-hSK, pCXLE-hUL and
pCXLEhOct3/4-shp53-F were used per experiment (Borchert et al.,
2017). Electroporation was done with the nucleofector II from Lonza
(program P22 or U23). Cells were plated in fibroblast medium with 5
µmol/L per survival factor and 500 µmol/L sodium butyrate. 7 days
after transfection the fibroblasts were passaged on Geltrex for picking
iPS-like colonies 2-3 weeks later. The iPSCs were cultivated with E8
medium (life technologies) and passaged every 3-4 days with versene
(0.48 mmol/L EDTA).
3.3. In vitro differentiation of ps-iPSCs
iPSCs were cocultured with mitotically inactivated mouse em-
bryonic fibroblasts in hES medium (DMEM/F12 supplemented with 10
% KOSR, 1x NEAA and 1x β-mercaptoethanol). With a confluency of
90% the cells were scraped into big clusters and passaged to an un-
coated 6 cm dish. Embryoid bodies (EBs) formation arised in suspen-
sion. After 2 days medium was changed to Iscove-Diff Medium (Iscove
basal medium, 5% FCS, 1x NEAA and 450 µmol/L monothioglycerol).
After 8 days of cultivation, EBs were replated and analyzed after further
8 or 25 days (Tables 1 and 2).
3.4. Immunocytochemical staining
Cells were fixed with 4% paraformaldehyde at room temperature for
20 minutes and blocked with 1% BSA. Primary antibody staining was
performed overnight at 4°C. Secondary antibodies were provided in 1%
BSA for 1 hour at 37°C. Nuclei staining was executed with 4.6-diamino-
2-phenylindole (DAPI, 0.2 ng/mL). Samples were mounted with
VectaShield. Used antibodies are listed in Table 3.
3.5. Semi-quantitative and quantitative polymerase chain reaction
RNA was isolated with the SV Total RNA Isolation System
(Promega). For cDNA synthesis DNase-treated RNA (200 ng), Murine
Leukaemia Virus Reverse Transcriptase and Oligo d(T)16 (Applied
Biosystems) were used. Semi-quantitative PCR was performed using
GoTaq polymerase. The PCR products were separated by electrophor-
esis on 2.5% agarose gels. Quantitative PCR was performed using the
iQ™ SYBR® Green Supermix (Bio-Rad) and the iQ™5 real-time PCR
detection system (Bio-Rad). All primers were listed in Table 3. GAPDH
was used as a housekeeping gene.
3.6. Karyotype analysis
iPSCs (50 – 60% confluent) were handled with Demecolcine (16 h,
100 ng/mL, life technologies) and treated with 0.075 M KCl for 45 min
at 37°C. Cells were fixed (Methanol:Acetic acid (3:1)), dropped onto
slides and dried for 72 h at RT. Chromosomes were stained with 9.3 %
Giemsa (Sigma Adrich). 15 metaphase spreads/cell line were analyzed
by IKAROS 5.8.13 software (Metasystems) in the Department of
Haematology and Medical Oncology, UMG.
3.7. Teratoma formation
Two 6 cm dishes (70% confluent) of the generated iPSC-lines were
injected subcutaneously into 8-week-old immunodeficient mice. Two
months after injection resulting teratomas were harvested, fixed in
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
UMGi145-A 10-TTS Female 84 Caucasian N/A Takotsubo syndrome
UMGi146-A 11-TTS Female 62 Caucasian N/A Takotsubo syndrome
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formalin and analyzed with hematoxylin and eosin staining.
3.8. Mycoplasma test
Mycoplasma tests are performed every 10 passages via lumines-
cence with the Lonza Mycoalert Plus-Kit.
3.9. STR analysis
STR analysis was performed by Eurofins Genomics.
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Classification Test Result Data
Morphology Photography Normal stem cell-like morphology Fig. 1 panel A
Phenotype Qualitative analysis Positive immuncytochemistry stainings of pluripotency markers: OCT4, SOX2,
LIN28, TRA1-60
Fig. 1 panel A
Quantitative analysis (RT-
qPCR)
The expression pattern of OCT4, SOX2, NANOG, LIN28, and GDF3 from 10-TTS
and 11-TTS correlate with the expression pattern of a published iPSC-line. Skin
fibroblasts (NC) show low expression of pluripotency genes.
Fig. 1 panel B
Genotype Karyotype (G-banding) and
resolution
46XX, Resolution 300 Fig. 1 panel C
Identity Microsatellite PCR (mPCR) OR
STR analysis
N/A N/A
STR analysis: 16 independent PCR-systems were tested. 10-TTS and 11-TTS
match to the specific host fibroblasts in all analyzed points





Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Negative Mycoplasma testing by luminescence Supplementary Figure 1
Differentiation potential Embryoid body formation and
teratoma formation
Differentiation in all three germ layers. 10-TTS and 11-TTS show expression of
α-smooth muscle actin, β-III-tubulin and α-feto protein. Both cell lines are
capable to generate teratoma formation in immunodeficient mice.
Figure 1 panel D and E





Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency marker Goat anti-OCT3/4 IgG 1:40 R&D, Minneapolis, Minnesota, USA, Cat# AF1759, RRID:AB_354975
Pluripotency marker Mouse anti-SOX2 IgG2a 1:50 R&D, Minneapolis, Minnesota, USA, Cat# MAB2018, RRID:AB_358009
Pluripotency marker Goat anti-LIN28 IgG 1:300 R&D, Minneapolis, Minnesota, USA, Cat# AF3757, RRID:AB_2234537
Pluripotency marker Mouse anti-TRA1-60 IgM 1:200 Abcam, Cambridge, United Kingdom, Cat# ab16288, RRID:AB_778563
Germlayer marker Rabbit anti-AFP IgG 1:100 Dako, Hamburg, Germany, Cat# A0008, RRID:AB_2650473
Germlayer marker Mouse anti-α-SMA IgG2a 1:3000 Sigma Aldrich, St. Louis, Missouri, USA, Cat# A2547, RRID:AB_476701
Germlayer marker Mouse anti-β-III-Tubulin 1:1000 BioLegend, San Diego, California, USA, Cat# MMS-435P, RRID:AB_2313773
Secondary antibody Cy3 goat-anti-mouse IgG+IgM 1:300 Jackson ImmunoResearch, Cambridge, UK, Cat# 111-165-045, RRID:AB_2338003
Secondary antibody Alexa Fluor 647 donkey- anti-rabbit IgG 1:1000 Thermo Fisher Scientific, Waltham, Massachusetts, USA; Cat# A-31573, RRID:AB_2536183
Secondary antibody Alexa Fluor 555 donkey-anti-goat IgG 1:1000 Thermo Fisher Scientific, Waltham, Massachusetts, USA, Cat# A-21432, RRID:AB_2535853
Secondary antibody Alexa Fluor 488 donkey-anti-mouse IgG 1:1000 Thermo Fisher Scientific, Waltham, Massachusetts, USA, Cat# A-21202, RRID:AB_141607
Secondary antibody Alexa Fluor 488 goat-anti-mouse IgG+IgM 1:500 Thermo Fisher Scientific, Waltham, Massachusetts, USA, Cat# A-10680, RRID:AB_2534062
Primers
Target Forward/Reverse primer (5′-3′)
Pluripotency marker (quantitative PCR) GDF3 TTCGCTTTCTCCCAGACCAAGGTTTC/ TACATCCAGCAGGTTGAAGTGAACAGCACC
Pluripotency marker (quantitative PCR) LIN28 AGTAAGCTGCACATGGAAGG/ ATTGTGGCTCAATTCTGTGC
Pluripotency marker (quantitative PCR) NANOG AGTCCCAAAGGCAAACAACCCACTTC/ ATCTGCTGGAGG CTGAGGTATTTCTGTCTC
Pluripotency marker (quantitative PCR) OCT4 GACAACAATGAAAATCTTCAGGAGA/ TTCTGGCGCCGGTTACAGAACCA
Pluripotency marker (quantitative PCR) SOX2 GCTACAGCATGATGCAGGACCA/ TCTGCGAGCTGGTCATGGAGTT
House-Keeping gene (quantitative PCR, semi-quantitative PCR) GAPDH GTCTCCTCTGACTTCAACAGCG/ ACCACCCTGTTGCTGTAGCCAA
Episomal vector expression (semi-quantitative PCR) EBNA-1 ATCAGGGCCAAGACATAGAGATG/ GCCAATGCAACTTGGACGTT
Episomal vector expression (semi quantitative-PCR) OCT3/4 (pla) CATTCAAACTGAGGTAAGGG/ TAGCGTAAAAGGAGCAACATAG
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Supplementary materials
Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.scr.2020.101746.
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